Skip to content

Upcoming 2013 Catalysts For Sarepta Therapeutics And Orphan Drug Eteplirsen

January 6, 2013

       The upcoming 2013 catalysts for Sarepta Therapeutics and orphan drug Eteplirsen for Duchenne Muscular Dystrophy (DMD) :

**** 1) January 9, 2013, 4:30 p.m. PT, Wednesday – Company Overview Presentation at the 31st J.P. Morgan Global Healthcare Conference. Chris Garabedian, Sarepta’s President and CEO, will be the presenter. The presentation will be webcast live under the events section of Sarepta Therapeutics’ website

2)  Plans to ask for a meeting with the FDA for scheduling a meeting for the 1st Quarter of 2013 to discuss asking for Accelerated Approval for Eteplirsen and to also discuss a Phase III clinical trial for Eteplirsen

3)  Investors probably will not be hearing about the results of the FDA meeting until about March – April 2013

4)  Plans are for a future meeting with the FDA about the chemistry, manufacturing, and controls (CMC)

5)  74-week Eteplirsen clinical trial data.

***   It is important to note that Sarepta Therapeutics’ closest DMD competitor, Prosensa, will have their CEO Hans Schikan presenting at the 31st Annual J.P. Morgan Global Healthcare Conference on Monday, January 7, 2013, 4.30pm PST, for the purpose of providing a corporate update to the investment community. Prosensa and GlaxoSmithKline (GSK)’s orphan drug Drisapersen is currently in late-stage Phase III clinical trials for DMD.

Copyright © 2012-2013, Orphan Druganaut Blog. All rights reserved.

Advertisements
Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: